Company intelligence / Profile preview

Hangzhou Ruomai Xingyi Pharmaceutical

Hangzhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Ruomai Xingyi Pharmaceutical is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of innovative metabolic therapies. The company focuses on next-generation treatments for metabolic disorders, including obesity, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). Its lead programs involve multi-agonist small molecules targeting the GLP-1, GIP, and glucagon receptors. Ruomai Xingyi aims to provide oral alternatives to injectable peptide therapies, leveraging its expertise in medicinal chemistry to improve patient compliance and therapeutic outcomes.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

RMX1001

Unknown

Beyond the preview

Go deeper on Hangzhou Ruomai Xingyi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hangzhou Ruomai Xingyi Pharmaceutical.

Explore the full profile